Market Place
Sourcing Support
Elicio Therapeutics Presents at BofA Healthcare Conference
30 Apr 2026 //
GLOBENEWSWIRE
Elicio Therapeutics Reports Inducement Grants
16 Apr 2026 //
GLOBENEWSWIRE
Elicio Therapeutics Reports Inducement Grants
17 Mar 2026 //
GLOBENEWSWIRE
Elicio Therapeutics Reveals 2025 Financials And Corporate Updates
12 Mar 2026 //
GLOBENEWSWIRE
Elicio Therapeutics at TD Cowen 46th Annual Healthcare Conference
25 Feb 2026 //
GLOBENEWSWIRE
Elicio Therapeutics Reports Inducement Grants
18 Feb 2026 //
GLOBENEWSWIRE
Elicio Therapeutics Reports Inducement Grants
16 Dec 2025 //
GLOBENEWSWIRE
Elicio Pharma Appoints Veteran CMC & Tech Ops Exec Marc J
19 Nov 2025 //
GLOBENEWSWIRE
Elicio Therapeutics Reveals Q3 2025 Financials And Corporate
13 Nov 2025 //
GLOBENEWSWIRE
Elicio Reports Strong mKRAS T Cell Responses In Ph2 AMPLIFY-7P
07 Nov 2025 //
GLOBENEWSWIRE
Elicio Therapeutics To Showcase Clinical Data at SITC 2025
03 Nov 2025 //
GLOBENEWSWIRE
Elicio Shows Strong T Cell Response In Ph 2 AMPLIFY-7P Trial
27 Oct 2025 //
GLOBENEWSWIRE
Elicio, MSK Start Ph 1 Pancreatic Cancer Trial of ELI-002 7P
29 Sep 2025 //
GLOBENEWSWIRE
Elicio Therapeutics Announces Inducement Grants
18 Sep 2025 //
GLOBENEWSWIRE
Elicio Publishes Updated ELI-002 Ph 1 Data in Nature Medicine
12 Aug 2025 //
GLOBENEWSWIRE
Elicio Therapeutics reports Q2 2025 financials and updates
07 Aug 2025 //
GLOBENEWSWIRE
IDMC Recommends Elicio`s ELI-002 7 P Study in Pancreatic Cancer
05 Aug 2025 //
GLOBENEWSWIRE
Elicio Therapeutics Secures $10 Million in Financing
04 Jun 2025 //
GLOBENEWSWIRE
Elicio Therapeutics Reports Q1 2025 Financial Results and Updates
13 May 2025 //
GLOBENEWSWIRE
Elicio Therapeutics Reports Inducement Grant to New Chief Strateg
16 Apr 2025 //
GLOBENEWSWIRE
Elicio Closes $10M Direct Offering Priced At-The-Market
30 Jan 2025 //
GLOBENEWSWIRE
Elicio Therapeutics Aligns With FDA On ELI-002 Strategy
22 Jan 2025 //
GLOBENEWSWIRE
Elicio Therapeutics Shares ELI-002 Results At ESMO 2024
12 Dec 2024 //
GLOBENEWSWIRE
Elicio Therapeutics Completes Enrollment in Ph 2 Amplify-7P Study
03 Dec 2024 //
GLOBENEWSWIRE
Elicio Therapeutics Reports Q3 2024 Results & Updates
13 Nov 2024 //
GLOBENEWSWIRE
Elicio Therapeutics Updates Data from AMPLIFY-7P Study at SITC
07 Nov 2024 //
GLOBENEWSWIRE
Elicio Therapeutic to Present Data at SITC & SU2C Innovation Summit
31 Oct 2024 //
GLOBENEWSWIRE
Elicio Therapeutics Reports Inducement Grants
16 Oct 2024 //
GLOBENEWSWIRE
Elicio Therapeutics Reports Inducement Grants
17 Sep 2024 //
GLOBENEWSWIRE
Elicio Therapeutics Announces Three Upcoming Presentations On Vaccines
13 Sep 2024 //
GLOBENEWSWIRE
Elicio Therapeutics To Present At H.C. Wainwright Conference
28 Aug 2024 //
GLOBENEWSWIRE
Elicio Therapeutics Reports Q2 2024 Results And Corporate Updates
13 Aug 2024 //
GLOBENEWSWIRE
Elicio Therapeutics Closes $20M Convertible Note Private Placement
12 Aug 2024 //
GLOBENEWSWIRE
Elicio Eli-002 Prelim Phase 1a: Mkras Tumors At 2024 Asco
23 May 2024 //
GLOBENEWSWIRE
Elicio`s ELI-002 mKRAS Data at ASCO 2024
25 Apr 2024 //
GLOBENEWSWIRE
Elicio Announces Publication of Data Demonstrating TCR-T Cell Therapy
25 Jan 2024 //
GLOBENEWSWIRE
Elicio to Present ELI-002 7P Trial in Progress Poster on Phase 1/2 Study
17 Jan 2024 //
GLOBENEWSWIRE
Elicio Announces First Patient Dosed in Phase 2 Pancreatic Cancer Study
11 Jan 2024 //
GLOBENEWSWIRE
Nature Medicine Publishes Updated Phase 1 Data From Elicio`s Study of ELI-002
09 Jan 2024 //
GLOBENEWSWIRE
Elicio Therapeutics Presents Data from the Ongoing Phase 1 Study of ELI-002
03 Nov 2023 //
GLOBENEWSWIRE
Elicio Therapeutics Presents Survival Data from the Phase 1 Study of ELI-002
27 Sep 2023 //
GLOBENEWSWIRE
Elicio Therapeutics Receives $2.6 Million Grant from the GI Research Foundation
07 Sep 2023 //
GLOBENEWSWIRE
Elicio Therapeutics to Present Phase 1 Data on Cancer Vaccine Candidate, ELI-002
05 Sep 2023 //
GLOBENEWSWIRE
Elicio Therapeutics Completes Reverse Merger and Provides a Corporate Update
06 Jun 2023 //
GLOBENEWSWIRE
Elicio Announces Positive Interim Data from the Phase 1 Study of ELI-002
03 Jun 2023 //
GLOBENEWSWIRE
Elicio to Present Interim Data from the Ongoing Phase 1 Study of ELI-002
01 May 2023 //
GLOBENEWSWIRE
Elicio Therapeutics Announces First Patient Dosed in Phase 1/2 Study
27 Apr 2023 //
GLOBENEWSWIRE
Cancer vaccine developer jumps to Nasdaq via reverse merger
17 Jan 2023 //
ENDPTS
